Intraperitoneal injection of LXA4 was shown to ameliorate EAE clinical symptoms and inhibit CD4+ and CD8+ T cell infiltration into the CNS; in addition, LXA4 potently reduced encephalitogenic Th1 and Th17 effector functions, both in vivo and in isolated human T cells from healthy donors and patients with RRMS [67]. The gene discussed is CD4; the disease is relapsing-remitting multiple sclerosis.